Debu Tripathy on Monitoring Patients with Breast Cancer on Oral Oncolytics
Debu Tripathy on the management of patients with breast cancer on oral oncolytics.
Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, discusses the important points for nurses to keep in mind when managing patients with breast cancer who are taking oral oncolytics.
The oral agents such as palbociclib (Ibrance) and everolimus (Afinitor) can come with side effects that cause patients to discontinue treatment. These are side effects such as mouth ulcers, with everolimus, and fatigue, with palbociclib. Nurses can be sure to anticipate these side effects, educate the patients on the possibilities, and monitor patients closely throughout treatment.